Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
These approvals mark significant progress for Venus Remedies in expanding its market presence
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Medicines, including insulin, to be available in 40 lower-income countries
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Tislelizumab is now approved for seven indications in China
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)